Click here to visit Original posting
Life sciences startups need a whole lot more cash than most and that’s certainly true for GRAIL, a cancer detection startup trying to figure out a way to find the “emperor of all maladies” much earlier through blood testing technology. The startup, which spun out of genomics company Illumina announced it has closed a whopping $900 million in Series B funding this morning.… Read More